AWM
INO icon

Aberdeen Wealth Management’s Inovio Pharmaceuticals INO Stock Holding History

Aberdeen Wealth Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220 Buy
+200
New +$237 ﹤0.01% 424

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aberdeen Wealth Management's INO Position: Q2 2026 in Review

Aberdeen Wealth Management opened a new position in Inovio Pharmaceuticals (INO) in Q2 2026: 200 shares worth $220. The stake represents ﹤0.01% of the portfolio and ranks #424 among its holdings.

103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Aberdeen Wealth Management held 200 shares of Inovio Pharmaceuticals worth $220 as of Q2 2026.
  • Inovio Pharmaceuticals was a new Aberdeen Wealth Management position in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Aberdeen Wealth Management's portfolio in Q2 2026, its #424 holding.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Aberdeen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.